- Home
- INGR vs ROIV Comparison
INGR vs ROIV Comparison
Compare INGR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INGR | ROIV |
|---|---|---|
| Founded | 1906 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 20.7B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INGR | ROIV |
|---|---|---|
| Price | $112.62 | $26.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $133.00 | $27.56 |
| AVG Volume (30 Days) | 547.9K | ★ 4.6M |
| Earning Date | 05-05-2026 | 02-06-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 15.14 | N/A |
| EPS | ★ 11.18 | N/A |
| Revenue | ★ $7,219,000,000.00 | $29,053,000.00 |
| Revenue This Year | $3.93 | N/A |
| Revenue Next Year | $2.79 | $594.84 |
| P/E Ratio | $10.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $102.31 | $8.73 |
| 52 Week High | $141.78 | $30.33 |
Technical Indicators
Market Signals| Indicator | INGR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 39.47 |
| Support Level | $109.25 | $20.46 |
| Resistance Level | $114.10 | $27.94 |
| Average True Range (ATR) | 2.24 | 0.87 |
| MACD | 0.22 | -0.41 |
| Stochastic Oscillator | 77.36 | 0.46 |
Price Performance
Historical ComparisonAbout INGR Ingredion Incorporated
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.